Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.

about

Correlation Between Ki-67 Index, World Health Organization Grade and Patient Survival in Glial Tumors With Astrocytic Differentiation.

P2860

Q41524081-DD2A826D-26B6-468F-AA20-29878846E648

P2860

Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.

Item

http://www.wikidata.org/entity/Q38836820

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Identification of MGMT promote ...... and IDH1 mutation in gliomas.

@en

type

Item

label

Identification of MGMT promote ...... and IDH1 mutation in gliomas.

@en

prefLabel

Identification of MGMT promote ...... and IDH1 mutation in gliomas.

@en

P1476

Identification of MGMT promote ...... and IDH1 mutation in gliomas.

@en

P2093

Hui-Juan Wang

http://www.w3.org/2001/XMLSchema#string

Jia Quan

http://www.w3.org/2001/XMLSchema#string

Jian-Hui Yang

http://www.w3.org/2001/XMLSchema#string

Jie Zhang

http://www.w3.org/2001/XMLSchema#string

Peng-Gao Dai

http://www.w3.org/2001/XMLSchema#string

Xing Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

The 2007 WHO classification of tumours of the central nervous system

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

The role of MGMT testing in clinical practice: a report of the association for molecular pathology

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Malignant gliomas in adults

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

P2888

s13277-016-5153-4

P304

13571-13579

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-016-5153-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026782567

http://www.w3.org/2001/XMLSchema#string

P698

27468718

http://www.w3.org/2001/XMLSchema#string

Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.

about

P2860

P2860

Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698